PTCT
PTC Therapeutics, Inc. · Healthcare
Insiders sold $56.0M of PTC Therapeutics, Inc. in the last 12 months and bought none
PTCT over the last year
PTCT after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
205 insider filings since 2017, newest first
Michael Schmertzler · Director
Michael Schmertzler · Director
Mark Elliott Boulding · Exec. VP and CLO
Glenn Jr Md Phd Steele · Director
Michael Schmertzler · Director
Michael Schmertzler · Director
Michael Schmertzler · Director
Michael Schmertzler · Director
Mark Elliott Boulding · Exec. VP and CLO
Matthew B. Klein · Chief Executive Officer
Pierre Gravier · Chief Financial Officer
Mary L. Smith · Director
Neil Gregory Almstead · Chief Technical OPS Officer
Mark Elliott Boulding · Exec. VP and CLO
Neil Gregory Almstead · Chief Technical OPS Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Christine Marie Utter · SVP and Chief Accounting Officer
Mark Elliott Boulding · Exec. VP and CLO
Eric Pauwels · Chief Business Officer
Mark Elliott Boulding · EVP and CLO
Matthew B. Klein · CEO
Mark Elliott Boulding · EVP and CLO
Matthew B. Klein · CEO
Mark Elliott Boulding · EVP and CLO
Lee Scott Golden · EVP and Chief Medical Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Matthew B. Klein · CEO
Stephanie Okey · Director
Lee Scott Golden · EVP and Chief Medical Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Stephanie Okey · Director
Mark Elliott Boulding · EVP and CLO
Matthew B. Klein · CEO
Lee Scott Golden · EVP and Chief Medical Officer
Neil Gregory Almstead · Chief Technical OPS Officer
Christine Marie Utter · SVP and Chief Accounting Officer
Pierre Gravier · CFO
Eric Pauwels · Chief Business Officer
Mark Elliott Boulding · EVP and CLO
Matthew B. Klein · CEO
Lee Scott Golden · EVP and Chief Medical Officer
Mark Elliott Boulding · EVP and CLO
Neil Gregory Almstead · Chief Technical OPS Officer
Christine Marie Utter · SVP and Chief Accounting Officer
Eric Pauwels · Chief Business Officer
Matthew B. Klein · CEO
Lee Scott Golden · EVP and Chief Medical Officer
Mark Elliott Boulding · EVP and CLO
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.